Connor Clark & Lunn Investment Management Ltd. Raises Stock Holdings in Atea Pharmaceuticals, Inc. (NASDAQ:AVIR)

Connor Clark & Lunn Investment Management Ltd. boosted its holdings in shares of Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) by 72.9% during the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 76,352 shares of the company’s stock after purchasing an additional 32,195 shares during the quarter. Connor Clark & Lunn Investment Management Ltd. owned approximately 0.09% of Atea Pharmaceuticals worth $256,000 at the end of the most recent quarter.

A number of other institutional investors also recently made changes to their positions in the business. BML Capital Management LLC increased its stake in shares of Atea Pharmaceuticals by 14.4% in the fourth quarter. BML Capital Management LLC now owns 7,608,312 shares of the company’s stock worth $25,488,000 after buying an additional 958,312 shares during the last quarter. FMR LLC increased its position in shares of Atea Pharmaceuticals by 2.8% in the 3rd quarter. FMR LLC now owns 6,618,297 shares of the company’s stock worth $22,171,000 after purchasing an additional 182,174 shares during the last quarter. State Street Corp increased its position in shares of Atea Pharmaceuticals by 0.7% in the 3rd quarter. State Street Corp now owns 1,733,486 shares of the company’s stock worth $5,807,000 after purchasing an additional 11,566 shares during the last quarter. Charles Schwab Investment Management Inc. raised its stake in shares of Atea Pharmaceuticals by 1.4% in the 4th quarter. Charles Schwab Investment Management Inc. now owns 659,527 shares of the company’s stock valued at $2,209,000 after purchasing an additional 9,370 shares in the last quarter. Finally, Peapod Lane Capital LLC bought a new position in shares of Atea Pharmaceuticals during the fourth quarter worth about $1,101,000. 86.67% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Separately, William Blair restated an “outperform” rating on shares of Atea Pharmaceuticals in a research note on Friday, March 7th.

Atea Pharmaceuticals Price Performance

Atea Pharmaceuticals stock opened at $3.22 on Monday. The company has a market cap of $275.39 million, a PE ratio of -1.56 and a beta of 0.18. Atea Pharmaceuticals, Inc. has a 12 month low of $2.75 and a 12 month high of $4.15. The company has a fifty day moving average price of $3.10 and a two-hundred day moving average price of $3.29.

Atea Pharmaceuticals (NASDAQ:AVIR) last announced its quarterly earnings data on Thursday, March 6th. The company reported ($0.40) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.35) by ($0.05). Equities research analysts anticipate that Atea Pharmaceuticals, Inc. will post -2.01 earnings per share for the current year.

Atea Pharmaceuticals Company Profile

Atea Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes antiviral therapeutics for patients with viral infections. Its lead product candidate is AT-527, an oral antiviral candidate that is in Phase 3 SUNRISE-3 clinical trial for the treatment of patients with COVID-19.